What is NDC 63020-049?

63020-049 is the product NDC for Velcade (bortezomib), Bortezomib 3.5 mg/1 injection, powder, lyophilized, for solution, listed with the FDA by Takeda Pharmaceuticals America, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Takeda Pharmaceuticals America, Inc., NDC labeler code 63020. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Velcade?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Velcade NDC 63020-049 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)63020-049Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63020-0049Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
63020-049-01	6302000490163020004901	1 VIAL in 1 CARTON (63020-049-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIALMarketed from May 13, 2003

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Velcade
Generic name (nonproprietary): bortezomib
Active ingredients: Bortezomib — 3.5 mg/1
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous, Subcutaneous
Labeler: Takeda Pharmaceuticals America, Inc.NDC labeler code 63020
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 021602
Marketing start: May 13, 2003
Listing expires: Dec 31, 2026
Other FDA classes: Proteasome Inhibitors (Mechanism)
Identifiers: Product ID 63020-049_3ec85e73-696a-4a2e-aa24-656c6341b23bSPL ID 3ec85e73-696a-4a2e-aa24-656c6341b23bSPL set ID 1521d321-e724-4ffc-adad-34bf4f44fac7RxCUI 402243, 402244UNII 69G8BD63PP
Pharmacologic class: Proteasome Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N463020004901 followed by a unit qualifier and the quantity

Package 63020-0049-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 28, 2025.

Indications (excerpt from the label)

VELCADE is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma VELCADE is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma VELCADE is indicated for the treatment of adult patients with mantle cell lymphoma.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 63020-049

What is NDC 63020-049?: 63020-049 is the product NDC for Velcade (bortezomib), Bortezomib 3.5 mg/1 injection, powder, lyophilized, for solution, listed with the FDA by Takeda Pharmaceuticals America, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Velcade (Bortezomib).
What is the active ingredient?: Bortezomib.
Who is the labeler?: Takeda Pharmaceuticals America, Inc., NDC labeler code 63020. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Velcade?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Velcade (Bortezomib) NDC 63020-049